ConductScience.org, home

Paper30615985

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.

Aroda VR and 8 others. Diabetes Metab, 2019. Cited by 229 papers, by iCite.

Cite this record

ConductScience Library. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Papers, record 30615985. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30615985

Download JSON
Disease
type 2 diabetes mellitus613 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
PubMed
Journal
Diabetes Metab
PubMed
Year
2019
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
229
iCite
Relative citation ratio, by iCite
9.7
iCite
Revised in PubMed
2026-01-27
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Aroda VRV R
2Ahmann AA
3Cariou BB
4Chow FF
5Davies MJM J
6Jódar EE
7Mehta RR
8Woo VV
9Lingvay II

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetes Mellitus, Type 2Major topic
Glucagon-Like PeptidesMajor topic
Hypoglycemic AgentsMajor topic
IncretinsMajor topic
Glucagon-Like Peptide-1 Receptor AgonistsMajor topic
Humans
Injections, Subcutaneous
Treatment Outcome
Semaglutide

Source PubMed

Download CSV of topics

Trials7

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01720446Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 DiabetesResultsClinicalTrials.gov
NCT01885208Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 DiabetesResultsClinicalTrials.gov
NCT01930188Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 DiabetesResultsClinicalTrials.gov
NCT02054897Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 DiabetesResultsClinicalTrials.gov
NCT02128932Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 DiabetesResultsClinicalTrials.gov
NCT02305381Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 DiabetesResultsClinicalTrials.gov
NCT02648204Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.ResultsClinicalTrials.gov

Download CSV of trials

Cited by139

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 229 citations.

PMIDTitleJournalYearIn PapersSource
42890485GLP-1 RA Eligibility in Reproductive-Age U.S. Women.Diabetes Obes Cardiometab CARE2026https://conductscience.org/library/papers/42890485PubMed
42747132Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review.Endocrinol Diabetes Metab2026https://conductscience.org/library/papers/42747132PubMed
42651699For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?Biology (Basel)2026https://conductscience.org/library/papers/42651699PubMed
42622874Investigating the impact of Glucagon-like peptide-1 therapy on total shoulder arthroplasty outcomes.Int Orthop2026https://conductscience.org/library/papers/42622874PubMed
42620396Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.Front Public Health2026https://conductscience.org/library/papers/42620396PubMed
42432542Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report.BMC Ophthalmol2026https://conductscience.org/library/papers/42432542PubMed
42403263Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study.Diabetes Obes Metab2026https://conductscience.org/library/papers/42403263PubMed
42305970A systematic review of semaglutide-associated kidney injury case reports.Front Med (Lausanne)2026https://conductscience.org/library/papers/42305970PubMed
42297449The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.Schizophr Bull2026https://conductscience.org/library/papers/42297449PubMed
42278227Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus.Int J Mol Sci2026https://conductscience.org/library/papers/42278227PubMed
42253408
Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus.
Metabol Open2026https://conductscience.org/library/papers/42253408PubMed
42232304Optimization of nursing strategies for semaglutide treatment in overweight type 2 diabetes based on gene polymorphism.Front Clin Diabetes Healthc2026https://conductscience.org/library/papers/42232304PubMed
42219226Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study.Diabetes Obes Metab2026https://conductscience.org/library/papers/42219226PubMed
42198407Oral GLP-1-Based Therapeutics in the Obesity-Metabolic Syndrome-Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42198407PubMed
42185271Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.Nat Commun2026https://conductscience.org/library/papers/42185271PubMed
42144979GLP-1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review.Alcohol Clin Exp Res (Hoboken)2026https://conductscience.org/library/papers/42144979PubMed
42099530Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective.Clinicoecon Outcomes Res2026https://conductscience.org/library/papers/42099530PubMed
42099097Exploring Weight Loss Medication Discourse: Mixed Methods Analysis of US-Based Facebook Posts.JMIR Infodemiology2026https://conductscience.org/library/papers/42099097PubMed
42072382Management Strategies for Congestive Heart Failure in Chronic Kidney Disease: Narrative Review.Biomedicines2026https://conductscience.org/library/papers/42072382PubMed
41984016Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus.J Am Coll Cardiol2026https://conductscience.org/library/papers/41984016PubMed

See all 139 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GCG2641PubTator's text mininghttps://conductscience.org/library/genes/2641NCBI Gene
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene

Download CSV of genes

Drugs5

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
INSULIN GLARGINECHEMBL1201497Results1https://conductscience.org/library/drugs/CHEMBL1201497ChEMBL
SITAGLIPTINCHEMBL1422Results1https://conductscience.org/library/drugs/CHEMBL1422ChEMBL
DULAGLUTIDECHEMBL2108027Results1https://conductscience.org/library/drugs/CHEMBL2108027ChEMBL
SEMAGLUTIDECHEMBL2108724Results7https://conductscience.org/library/drugs/CHEMBL2108724ChEMBL
EXENATIDECHEMBL414357Results1https://conductscience.org/library/drugs/CHEMBL414357ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30615985

GET https://conductscience.org/api/papers/v1/30615985/cited_by?page=2